RT Journal Article SR Electronic T1 Targeting persistent changes in neuroimmune and epigenetic signaling in adolescent drinking to treat alcohol use disorder in adulthood JF Pharmacological Reviews JO Pharmacol Rev FD American Society for Pharmacology and Experimental Therapeutics SP PHARMREV-AR-2022-000710 DO 10.1124/pharmrev.122.000710 A1 Fulton T. Crews A1 Leon G Coleman, Jr. A1 Victoria A. Macht A1 Ryan P Vetreno YR 2022 UL http://pharmrev.aspetjournals.org/content/early/2022/12/12/pharmrev.122.000710.abstract AB Studies universally find early age of drinking onset is linked to lifelong risks of alcohol problems and alcohol use disorder (AUD). Assessment of the lasting impact of drinking during adolescent development in humans is confounded by the diversity of environmental and genetic factors that impact adolescent development, including emerging personality disorders and progressive increases in drinking trajectories into adulthood. Preclinical studies using an adolescent intermittent ethanol (AIE) exposure rat model of underage binge drinking avoid the human confounds and support lifelong changes increasing risks. AIE increases adult alcohol drinking, risky decision-making, and reward seeking and anxiety as well as reductions in executive function that all increase risks for development of an AUD. AIE causes persistent increases in brain neuroimmune signaling HMGB1, TLR, RAGE and innate immune genes that are also found to be increased in human AUD brain. HMGB1 is released from cells by ethanol, both free and within extracellular vesicles (EV), that act on neurons and glia, shifting transcription and cellular phenotype. AIE-induced decreases in adult hippocampal neurogenesis and loss of basal forebrain cholinergic neurons are reviewed as examples of persistent AIE-induced pathology. Both are prevented and reversed by anti-inflammatory and epigenetic drugs. Findings suggest AIE-increased HMGB1 signaling induces the RE-1 silencing transcript blunting cholinergic gene expression, shifting neuronal phenotype. Inhibition of HMGB1 neuroimmune signaling, histone methylation enzymes, and galantamine, the cholinesterase inhibitor, both prevent and reverse AIE pathology. These findings provide new targets that may reverse AUD neuropathology as well as other brain diseases linked to neuroimmune signaling. Significance Statement Adolescent underage binge drinking studies find that earlier adolescent drinking is associated with lifelong alcohol problems including high levels of lifetime alcohol use disorder (AUD). Preclinical studies find the underage binge drinking adolescent intermittent ethanol (AIE) model causes lasting changes in adults that increase risks of developing adult alcohol problems. Loss of hippocampal neurogenesis and loss of basal forebrain cholinergic neurons provide examples of how AIE-induced epigenetic and neuroimmune signaling provide novel therapeutic targets for adult AUD.